U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Providence Gold Reports Up to 8.0 g/t Au from Mojave Girl Stockpile Sampling; Phase 2 Evaluation at Tarantula Site To Begin
Silver Hammer Commences Summer Exploration Program at Its Strategically Located Fahey Silver Project in the Silver Valley of Idaho
